About
Before joining Brandon Capital Chris was a Business Development Manager with CSL, Australia’s largest pharmaceutical company. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. Earlier Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK. Chris is currently a director of; Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera, and Axelia Oncology. Chris has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Immunology at the Walter and Eliza Hall Institute, and an MBA from the University of Cambridge, specializing in innovation and entrepreneurship. Chris is a graduate of the Australian Institute of Company Directors.
Investment Focus
- Location
- US
Contact Information
Find more investors like Christopher
Search Investors